Market Size of Human Papillomavirus Vaccine Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 7.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Human Papillomavirus Vaccine Market Analysis
The human papillomavirus (HPV) vaccine market is expected to register a CAGR of nearly 7.5% during the forecast period.
As the pandemic hit, the screening and diagnosis of non-emergency diseases were postponed worldwide, which has impacted the studied market. As per a research study published in March 2021 in PubMed, 74% of the total respondent laboratories globally experienced a supply shortage for HPV tests for cervical cancer screening. Therefore, there was a reduction in cervical cancer and other related cancer screening, ultimately reducing the demand for the HPV vaccine during the pandemic. Furthermore, a research study published in January 2023 in Vaccines indicated that a 75% reduction in HPV vaccination coverage was observed in the United States during the initial phase of the pandemic as compared to the previous year. Hence, owing to the factors mentioned above, the COVID-19 pandemic significantly impacted the market studied. However, with the COVID-19 cases in control, the market regained its pre-pandemic nature in terms of demand for HPV vaccines. Furthermore, due to the increasing initiatives by government & private organizations for early screening & vaccination and approval of new HPV vaccines, the market is believed to witness significant growth over the forecast period.
The rising prevalence of HPV-related diseases such as cervical cancer, anal cancer, and genital warts is expected to boost the demand for HPV vaccines significantly. For instance, as per the India, HPV and Related Cancers, 2023 report, cervical cancer ranks as the 2nd most frequent cancer among women in India and the 2nd most frequent cancer among women between 15 and 44. As per the same source, 123,907 women are diagnosed with cervical cancer in India each year. Therefore, the high burden of cervical cancer is expected to boost the demand for HPV vaccine during the forecast period.
The initiatives by the government to fund the HPV vaccines and rising screening and immunization programs are expected to boost the market growth. For instance, according to an article published in January 2023 in Vaccines Journal, the HPV vaccine is fully funded for children aged 11-14 years old and for 15-26-year-old females in Switzerland. Also, in March 2022, in Greece, a gender-neutral HPV vaccination program was launched.
Furthermore, in January 2021, the United States Department of Health and Human Services launched the "HPV VAX NOW" campaign to increase HPV vaccination rates among young adults aged 18-26 years. Also, in November 2021, Saudi Arabia launched a human papillomavirus infection program for young girls aged 9-13 years to prevent them from developing cervical cancer. This is expected to increase the development of HPV-cervical cancer vaccines hence bolstering the market growth.
Therefore, the factors such as the high burden of cervical cancer and rising screening and immunization programs, and launches of vaccines, the studied market is expected to witness growth during the forecast period. However, stringent regulation is likely to hinder market growth over the forecast period.
